ILD news you may have missed
Click Here to Manage Email Alerts
Healio Pulmonology has compiled a list of articles highlighting the latest research and news on diagnosis and treatment for interstitial lung disease.
See below for links to studies on potential therapies for ILD, including pirfenidone, approval of nintedanib (Ofev, Boehringer Ingelheim) for a rare type of ILD and the use of transbronchial lung cryobiopsy for ILD diagnosis.
INBUILD: Nintedanib slows progression of fibrosing ILD
When compared with placebo, nintedanib slowed the annual rate of decline in FVC in patients with progressive fibrosing ILD other than idiopathic pulmonary fibrosis, researchers reported at the European Respiratory Society International Congress. Read more
FDA approves nintedanib for systemic sclerosis-associated ILD
The FDA has approved nintedanib capsules to slow the rate of decline in pulmonary function in adults with ILD associated with systemic sclerosis or scleroderma, according to a press release. Read more
Pirfenidone promising for unclassifiable ILD
Pirfenidone treatment was associated with improvement in several outcomes among patients with progressive fibrosing unclassifiable ILD, according to a new study. Read more
Study lays groundwork for understanding RA-ILD/RA-IPF overlap
Comparative serum protein biomarker profiling may allow researchers to identify patients with rheumatoid arthritis-associated ILD and/or IPF, according to findings published in Arthritis Rheumatology. Read more
Agreement high between cryobiopsy, surgical biopsy for ILD diagnosis
New data demonstrating good agreement between transbronchial lung cryobiopsy and surgical lung biopsy support the use of the technology as an alternative to surgical biopsy for patients requiring lung tissue for a diagnosis of ILD. Read more